Core Insights - VolitionRx Limited has published a study on nucleosome detection in healthy cats, marking a significant advancement in veterinary diagnostics [1][3] - The study indicates the potential for cancer screening and monitoring in cats, which could represent a substantial commercial opportunity for the company [2][4] Company Developments - The study confirms that H3.1 nucleosomes can be quantified from blood samples of healthy cats, establishing a protocol for sample collection and processing [3] - Volition's initial target product focuses on feline lymphoma, the most prevalent cancer in cats, with clinical studies already in progress [4] Market Potential - There are over 60 million cats in the U.S., with 25% classified as senior cats, indicating a significant market for annual health checks [2] - The development of Nu.Q® products for cats opens new avenues for Volition in the veterinary diagnostics market [2][4] Research and Development - Volition's R&D activities are primarily based in Belgium, with additional facilities in the U.S. and London, emphasizing the company's international presence [6]